Results 11 to 20 of about 466,931 (209)
Prognostic impact of hypochromic erythrocytes in patients with pulmonary arterial hypertension
Respiratory Research, 2021 Background Iron deficiency affects up to 50% of patients with pulmonary arterial hypertension (PAH) but iron markers such as ferritin and serum iron are confounded by several non-disease related factors like acute inflammation and diet.
Panagiota Xanthouli +13 more
doaj +1 more source
American Journal of Respiratory and Critical Care Medicine, 2015 Pulmonary hypertension is said to occur when the mean pulmonary arterial pressure exceeds 25 mmHg at rest or 30 mmHg during exercise. There are many causes but the term Pulmonary arterial hypertension (PAH) is used to describe a rare group of illnesses that share histopathological similarities in the small muscularised pulmonary arterioles leading to ...
Ali Ataya, Johan Barretto, John Wynne
openaire +4 more sources
Respiratory Research, 2018 Background The objective of this study was to assess, whether right atrial (RA) and ventricular (RV) size is related to RV pump function at rest and during exercise in patients with pulmonary arterial hypertension (PAH).
Lukas Fischer +12 more
doaj +1 more source
ERJ Open Research, 2023 Research questions Patients with severe pulmonary hypertension associated with chronic lung disease have a poor prognosis. Targeted pulmonary arterial hypertension therapies might improve exercise capacity and outcome, but there are no guidelines on ...
Romain Naud +10 more
doaj +1 more source
BMC Pulmonary Medicine, 2017 Background Chronic inflammation emerges as a feature of the pathogenesis of pulmonary arterial hypertension (PAH) in experimental models. Alterations of circulating cell subsets have been observed in patients with PAH.
Lars Harbaum +9 more
doaj +1 more source
Life, 2023 Advances in the diagnosis and treatment of pulmonary hypertension (PH) have gradually improved the disease course. This retrospective cohort study aims to explore the diagnostic hemodynamic profile and survival of PH patients and their temporal changes ...
Georgios E. Papadopoulos +12 more
doaj +1 more source
Macitentan in daily clinical practice: A single centre, 1-year experience
Pulmonology, 2018 The effectiveness and safety of macitentan, a dual endothelin-receptor antagonist (ERA) approved for the treatment of pulmonary arterial hypertension (PAH), were shown in an extensive clinical trial oriented towards morbidity and mortality events.
S. Cadenas-Menéndez +5 more
doaj +3 more sources
Pulmonary Circulation, 2019 A 36-year-old woman presented with recurrent pulmonary emboli (PE) despite oral anticoagulation. She was a type I diabetic with severe gastroparesis requiring insertion of multiple long-term peripherally inserted central catheters (PICC) over a 10-year ...
Abigail Masding +10 more
doaj +1 more source
Pulmonary hypertension associated with left-sided heart disease
Swiss Medical Weekly, 2017 Pulmonary hypertension associated with left-sided heart disease (PH-LHD) is the most common type of pulmonary hypertension. In patients with left-sided heart disease, the presence of pulmonary hypertension is typically a marker of more advanced disease,
Micha T. Maeder +5 more
doaj +1 more source
Pulmonary Circulation, 2022 Even though pulmonary arterial hypertension (PAH) remains an incurable disease, the combination of PAH‐specific therapies allowed treatment strategies to evolve from symptom‐based ones to others that aim to move patients to low‐risk conditions ...
Abdullah M. Aldalaan +7 more
doaj +1 more source